Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24).

Wüthrich P, Martenet M, Buri P

Pharmaceutical research1 Feb 1994Cited by 16 (Europe PMC)

PMID8165188DOI10.1023/a:1018915710318PepBankPUB-08165188

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, tetracosactide nasal bioavailability was 4.4%, compared with 24% after intramuscular administration.
In plain wordsIn rats, tetracosactide nasal bioavailability was lower than after intramuscular injection.
Peptide
Cosyntropin
Outcome
DecreaseNasal versus intramuscular bioavailability
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Intramuscular tetracosactide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Bioavailability
4.4%
nasal
Bioavailability
24%
intramuscular
Source sentences
Summary
Nasal bioavailability was low (4.4%) compared to i.m. (24%).
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518801
02AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, poloxamer 407 yielded a nonsignificant decrease in nasal tetracosactide bioavailability to 4%.
In plain wordsIn rats, poloxamer did not significantly improve nasal tetracosactide bioavailability compared with the simple formulation.
Peptide
Cosyntropin
Outcome
No significant changeBioavailability with poloxamer vehicle
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Nasal saline tetracosactide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Bioavailability
4%
poloxamer vehicle
Source sentences
Summary
Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%).
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518802
03AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, adding poloxamer 407 did not improve tetracosactide kinetic profiles.
In plain wordsIn rats, poloxamer did not improve tetracosactide kinetics compared with the simple formulation.
Peptide
Cosyntropin
Outcome
No significant changeKinetic profile with poloxamer vehicle
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Nasal saline tetracosactide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Source sentences
Summary
Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%).
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518803
04AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, the sodium glycocholate formulation increased tetracosactide absorption threefold compared with the simple formulation.
In plain wordsIn rats, nasal tetracosactide with sodium glycocholate produced threefold greater absorption than the simple formulation.
Peptide
Cosyntropin
Outcome
IncreaseAbsorption with sodium glycocholate
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Simple nasal formulation
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Absorption increase
3 fold
sodium glycocholate versus simple formulation
Source sentences
Summary
Moreover, absorption was increased threefold compared to the simple formulation.
4 context sentences(design, population, supporting numbers)
Summary · context
The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long.
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518804
05AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, tetracosactide with sodium glycocholate reached Tmax at 5 min, but the effect did not last long.
In plain wordsIn rats, nasal tetracosactide with sodium glycocholate peaked at 5 min, but the effect was brief.
Peptide
Cosyntropin
Outcome
Not applicableTime to peak with sodium glycocholate
Study
ratsn: not reported in source
Anesthetized rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Tmax
5 min
sodium glycocholate formulation
Source sentences
Summary
The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long.
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518805
06AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, tetracosactide with bacitracin reached maximum plasma levels after 15 min.
In plain wordsIn rats, nasal tetracosactide with bacitracin reached its highest blood level after 15 min.
Peptide
Cosyntropin
Outcome
Not applicableTime to peak with bacitracin
Study
ratsn: not reported in source
Anesthetized rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Time to maximum plasma level
15 min
bacitracin formulation
Source sentences
Summary
On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518806
07AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, the bacitracin formulation increased tetracosactide bioavailability to 24%.
In plain wordsIn rats, nasal tetracosactide with bacitracin increased bioavailability compared with the simple formulation.
Peptide
Cosyntropin
Outcome
IncreaseBioavailability with bacitracin versus simple formulation
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Simple nasal formulation
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Bioavailability
24%
bacitracin formulation
Source sentences
Summary
On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518807
08AnimalAnimal study (in vivo)Pharmacokinetics
In anesthetized rats, nasal tetracosactide with bacitracin achieved 24% bioavailability, as much as an intramuscular injection.
In plain wordsIn rats, nasal tetracosactide with bacitracin achieved the same bioavailability as an intramuscular injection.
Peptide
Cosyntropin
Outcome
Not applicableBioavailability with bacitracin versus intramuscular administration
Study
ratsn: not reported in source
Anesthetized rats
Comparator
Intramuscular tetracosactide
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intranasalAs given in this study (rats).
Measurements
Bioavailability
24%
bacitracin formulation
Source sentences
Summary
On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.
3 context sentences(design, population, supporting numbers)
Summary · context
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration.
Summary · context
The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers.
Summary · context
Tetracosactide plasma levels were monitored with radioimmunoassay.
Report a problemFND-0816518808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.